Vascular cognitive impairment, characterized by deficits in memory, attention, and executive function, occurs as a consequence of chronic cerebral hypoperfusion. Hypoperfusion leads to progressive neuronal damage, increased neuroinflammation, and subsequent cognitive deterioration. Traditional treatment strategies have largely been symptomatic, with limited success in modifying underlying pathophysiology. By leveraging HBOT—a method established for enhancing tissue oxygen saturation—scientists have investigated its potential to restore cerebral microenvironment homeostasis and counteract VCI progression at a molecular level.

Hyperbaric oxygen therapy functions by delivering oxygen at pressures exceeding atmospheric levels, significantly increasing plasma oxygen content and fostering elevated tissue oxygenation. This phenomenon is crucial for neurorepair mechanisms in ischemic and hypoxic brain conditions. In the present research, the therapeutic regimen consisted of controlled HBOT sessions applied to a well-validated mouse model of VCI induced by bilateral common carotid artery stenosis, simulating prolonged cerebral hypoperfusion. This design ensures translational relevance, as it mirrors vascular contributions to cognitive dysfunction observed clinically.

Central to the study’s novel findings is the modulation of microRNA-137-3p (miR-137-3p), a small non-coding RNA molecule known to regulate gene expression post-transcriptionally. The researchers discovered that HBOT significantly upregulated miR-137-3p levels in the hippocampus and cortex—regions critically involved in learning and memory. This upregulation was linked to downstream inhibition of tumor necrosis factor receptor-associated factor 3 (TRAF3), a pivotal adaptor protein that orchestrates inflammatory signaling pathways, including NF-κB and MAPK cascades, thereby influencing neuroinflammation and cell survival.

Analyzing neuroinflammatory markers, the team reported a robust decrease in pro-inflammatory cytokines such as TNF-α and IL-1β post-HBOT, correlating with reduced microglial activation. Microglia, the brain’s resident immune cells, are known to exacerbate neuronal injury when chronically activated. This inflammatory suppression via the miR-137-3p/TRAF3 axis highlights a critical neuroprotective mechanism by which HBOT mitigates secondary damage resulting from hypoperfusion-induced inflammation.

Notably, behavioral assessments in the treated mice revealed pronounced improvements in spatial memory and cognitive flexibility, as evaluated by the Morris Water Maze and Y-maze tests. These behavioral outcomes provide functional validation for the molecular alterations observed, firmly positioning HBOT as a potential disease-modifying intervention rather than merely symptomatic relief. The cognitive benefits evidenced in the mouse model evoke optimism for clinical adaptability in human populations suffering from vascular contributions to cognitive impairment and dementia (VCID).

Further histopathological examination elucidated that HBOT promoted neuronal survival and synaptic integrity. Quantitative analyses displayed increased expression of synaptic proteins, such as PSD-95 and synaptophysin, alongside attenuation of apoptotic markers like cleaved caspase-3 in treated animals. Preservation of synaptic connectivity is essential for maintaining neuronal circuitry that underpins cognition, reinforcing the therapeutic promise of HBOT in neurodegenerative diseases marked by synaptic loss.

The translational implications of this study resonate profoundly within the neuroscience and clinical communities. Current pharmacological interventions for VCI lack robust efficacy and are often accompanied by adverse effects. In contrast, HBOT is emerging as a non-invasive strategy with the potential to target multiple pathogenic facets of vascular cognitive impairment. Its capacity to modulate microRNA expression and dampen neuroinflammation introduces a paradigm shift in therapeutic design, paving the way for next-generation precision medicine.

From a mechanistic perspective, the delineation of the miR-137-3p/TRAF3 pathway unravels new targets for drug development. MicroRNAs are attractive candidates for therapeutic manipulation due to their fine-tuning capabilities of gene networks. Understanding the intricacies of their regulation by oxygen levels and inflammatory signals could inspire novel combinatorial treatments that synergize with HBOT, amplifying neuroprotective outcomes.

Equally, the study ignites curiosity about the duration, dosage, and timing parameters of HBOT to maximize efficacy and minimize possible oxygen toxicity. Optimization of these protocols in preclinical models can accelerate forward translation into human trials testing HBOT for mild cognitive impairment (MCI) and early-stage dementia attributed to vascular pathology. Safety profiles of HBOT are well-documented in other contexts, supporting its feasibility as a viable clinical intervention for neurological conditions.

The intricate balance between oxygen supply, oxidative stress, and cellular metabolism forms a biochemical milieu crucial to brain health. By enhancing oxygen availability, HBOT may recalibrate this balance, restoring mitochondrial function and energy production impaired in chronic hypoperfusion states. This metabolic restoration likely complements the anti-inflammatory and gene regulatory effects observed, creating a multidimensional therapeutic landscape.

Moreover, the research underlines the importance of mitochondrial dynamics and energy homeostasis linked to microRNA regulatory networks. Such insights expand the conceptualization of neuroprotection beyond classical inflammatory suppression to encompass broader metabolic resilience mechanisms orchestrated at the epigenetic and post-transcriptional levels.

In summary, the investigation conducted by Yang and colleagues compellingly argues for hyperbaric oxygen therapy as a formidable intervention against vascular cognitive impairment through molecular modulation of the miR-137-3p/TRAF3 pathway. The synthesis of neuroinflammatory control, synaptic preservation, and functional cognitive improvements underscores a holistic neuroprotective strategy with transformative clinical potential.

Future research should aim to explore synergistic effects between HBOT and emerging neurorestorative agents, potentially harnessing multimodal approaches for combating VCI. Longitudinal studies assessing sustained cognitive improvements and quality of life metrics will be crucial to cement HBOT’s role in standard care protocols. Additionally, investigations into patient stratification biomarkers may help personalize therapy to those most likely to benefit from oxygen-based modulation of microRNA pathways.

The findings herald a new chapter in neurovascular therapeutics, where oxygen—a fundamental element—proves to be a powerful modulator of gene expression and inflammatory circuits, capable of rewiring the brain’s response to injury. As the global burden of vascular dementia rises with aging populations, such innovative treatments offer a beacon of hope for millions affected by cognitive decline worldwide.

Subject of Research: Neuroprotective effects of hyperbaric oxygen therapy on vascular cognitive impairment in hypoperfused mice via miR-137-3p/TRAF3 pathway

Article Title: Neuroprotective effects of hyperbaric oxygen therapy on vascular cognitive impairment in hypoperfused mice via miR-137-3p/TRAF3 pathway

Article References:
Yang, L., Zhu, HZ., Xie, L. et al. Neuroprotective effects of hyperbaric oxygen therapy on vascular cognitive impairment in hypoperfused mice via miR-137-3p/TRAF3 pathway. Transl Psychiatry (2025). https://doi.org/10.1038/s41398-025-03771-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-025-03771-z

At the core of this paradigm lies microglia, whose functions extend far beyond immune surveillance. During brain development, the metabolic pathways within microglia and neurons coordinate to orchestrate synaptic pruning, neuronal growth, and network refinement. The metabolic crosstalk ensures that microglia can respond appropriately to neuronal signals, modulating energy utilization to support neurogenesis and synaptic plasticity. This fine-tuned metabolic symbiosis crucially influences the establishment of functional neural circuits foundational for cognition.

In adult brains, this microglia-neuron metabolic axis continues to play a pivotal role, sustaining cognition by regulating neuroinflammation and neuronal energy demands. Microglia adapt their metabolic states dynamically, switching between glycolysis and oxidative phosphorylation depending on the neural environment and the organism’s systemic metabolic status. Such plasticity guarantees that the brain can maintain homeostasis and adapt to fluctuating physiological conditions without compromising cognitive integrity.

However, the story takes a darker turn with ageing. Here, the tightly regulated metabolic communication between microglia and neurons deteriorates, leading to increased neuroinflammatory signaling and impaired energy metabolism. Age-associated mitochondrial dysfunction in microglia fosters a pro-inflammatory phenotype that disrupts neuronal metabolic support. Consequently, cognitive decline ensues, highlighting cellular metabolism as a cornerstone of neurodegeneration pathways. These findings suggest that metabolic dysregulation within the neuroimmune milieu is a key culprit behind the cognitive deficits observed in elderly populations.

Moreover, metabolic disorders such as diabetes mellitus further exacerbate this dysfunction. Hyperglycemia-induced oxidative stress and systemic inflammation reverberate in the brain’s microenvironment, perturbing microglial metabolism and neuronal energy homeostasis. These alterations create a vicious cycle, amplifying neuroinflammatory responses and impairing synaptic function. The mechanistic insights confirm that peripheral metabolic health is intricately linked to central nervous system functionality, emphasizing the need for integrated therapeutic strategies.

Neuroinflammatory diseases illustrate another facet of this metabolic interdependence. Conditions like multiple sclerosis and Alzheimer’s disease exhibit characteristic metabolic shifts within microglia, including altered lipid metabolism and impaired autophagy. Such changes not only influence microglial activation states but also directly compromise neuronal survival and synaptic integrity. Targeting these metabolic checkpoints holds promise for modulating disease progression by restoring immunometabolic balance.

Importantly, microglial metabolic pathways are finely tuned during brain development stages, involving key regulatory molecules such as mTOR and AMPK. These molecules act as metabolic sensors and orchestrators, integrating environmental cues and energy status to calibrate microglial functions. The downstream effects impact neurotrophic support and synaptic remodeling—processes integral to cognitive maturation and plasticity. Dissecting these pathways at a molecular level opens avenues for therapeutic modulation during critical developmental windows.

In parallel, neuronal metabolism itself undergoes modulation by microglial biochemical outputs. The release of metabolites and cytokines from microglia can enhance or suppress neuronal mitochondrial function, influencing the efficiency of ATP production required for neurotransmission and plasticity. This mutual metabolic regulation cements the concept of microglia not merely as immune sentinels but as metabolic partners essential for cognitive health.

Emerging technologies such as single-cell metabolomics and high-resolution imaging have been instrumental in unraveling these complex metabolic exchanges. These methodologies enable the visualization and quantification of metabolic fluxes and signaling molecules in situ, providing unprecedented resolution into microglia-neuron interactions. As a result, researchers can now chart temporal and spatial metabolic landscapes, correlating them directly with cognitive outcomes.

On the therapeutic front, metabolic interventions targeting microglial function are gaining increasing attention. Agents that modulate microglial metabolism, such as those activating mitochondrial biogenesis or promoting anti-inflammatory metabolic states, show potential in preclinical models to enhance cognitive resilience. Such strategies herald a new era in neurotherapeutics, moving beyond symptom management to precise metabolic reprogramming.

Furthermore, lifestyle factors influencing systemic metabolism, including diet and exercise, indirectly affect microglial metabolic states and neuronal function. Nutritional compounds with antioxidant and anti-inflammatory properties can recalibrate neuroimmune metabolism, underscoring the holistic nature of brain health management. This integrative perspective advocates for multifaceted approaches combining lifestyle modification with targeted pharmacological interventions.

Critically, understanding the bidirectional metabolic dialogue also offers insights into brain plasticity under stress and injury. During neuroinflammation or after trauma, microglial metabolic reprogramming dictates the balance between neuroprotection and neurotoxicity. Fine-tuning this balance could enhance recovery processes and mitigate long-term cognitive impairments.

The dynamic neuroimmune-metabolic interface also extends implications for cognitive disorders beyond classical neurodegeneration, including psychiatric illnesses where neuroinflammation and metabolic abnormalities coexist. Investigating microglia-neuron metabolic axes could unravel new pathological mechanisms and therapeutic targets in these domains.

As the field advances, it becomes clear that the metabolic engine driving cognition is not solely neuronal but is a collaborative output of neuron and microglia interaction. This recognition shifts paradigms, highlighting that maintaining metabolic harmony within this cellular duet is vital for sustaining cognitive function through life’s span and disease.

This comprehensive mechanistic understanding sets the stage for innovative research, inspiring the design of novel biomarkers and therapies aimed at fortifying the neuroimmune metabolic nexus. The convergence of immunology, metabolism, and neuroscience stands poised to revolutionize our approach to cognitive health, with far-reaching implications for ageing societies worldwide.

In conclusion, deciphering the intricacies of microglia-neuron metabolic interactions represents a frontier in neuroscience, offering hope for ameliorating cognitive impairment across a spectrum of disorders. By targeting the metabolic determinants of brain resilience, science moves closer to unlocking the full potential of cognitive longevity in both health and disease.

Subject of Research: Interactions between microglia and neurons focusing on metabolic pathways influencing cognition in health, ageing, and neurological diseases.

Article Title: The metabolic engine of cognition: microglia–neuron interactions in health, ageing and disease.

Article References:
Asimakidou, E., Pluchino, S., Silva, B.A. et al. The metabolic engine of cognition: microglia–neuron interactions in health, ageing and disease. Nat Metab (2025). https://doi.org/10.1038/s42255-025-01409-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s42255-025-01409-4

Schizophrenia, affecting approximately 1% of the global population, is marked by positive symptoms such as hallucinations and delusions, negative symptoms including social withdrawal, and pervasive cognitive impairments. These cognitive impairments significantly disrupt daily functioning and quality of life but remain challenging to address therapeutically. The study, conducted by Luan et al., investigates whether aberrant inflammatory responses detectable in peripheral blood can not only provide biomarkers for disease status but also illuminate mechanisms by which immune dysregulation impacts cognition.

This study utilized a cohort of 40 schizophrenia patients undergoing monotherapy with olanzapine, a widely prescribed atypical antipsychotic, paired with 40 matched healthy controls. Employing a sophisticated flow cytometric immunoassay and fluorescently encoded microspheres, the researchers quantified a panel of inflammatory factors in peripheral blood samples. Simultaneously, symptom severity was evaluated through the Positive and Negative Syndrome Scale (PANSS), while cognitive function assessments were conducted using the MATRICS Consensus Cognitive Battery (MCCB), capturing domains from processing speed to attention and working memory.

Intriguingly, the findings revealed that two chemokines—Eotaxin and Monocyte Chemoattractant Protein-1 (MCP1)—were significantly elevated in schizophrenia patients compared to healthy controls. These molecules, long recognized for their roles in neuroinflammation and neuroimmune communication, emerged as key biological signals potentially linking peripheral immune activation with central nervous system pathology.

Advanced statistical analyses, including LASSO regression and the Boruta feature selection algorithm, pinpointed Eotaxin and MCP1 as the most predictive inflammatory markers distinguishing patients from controls with robust discriminatory power. The resulting model achieved an area under the curve (AUC) of 0.838, underscoring its reliability and potential clinical relevance as an adjunct diagnostic tool.

Interestingly, while the elevated inflammatory markers showed no significant correlation with PANSS scores, an established measure of psychotic symptom severity, they demonstrated strong negative associations with cognitive performance. Eotaxin correlated negatively across all measured cognitive domains, suggesting a broad impact on cognitive integrity. Meanwhile, MCP1 showed more selective correlations, notably with processing speed and attention/vigilance, highlighting its possible role in discrete cognitive impairments.

These differential associations underscore the complex pathophysiology of schizophrenia, where immune-related processes may selectively impair neural circuits supporting cognitive functions rather than directly modulating psychotic symptoms. This supports an evolving paradigm viewing schizophrenia as a multisystem disorder with intertwined neuroimmune etiologies.

The biological plausibility of these findings rests on growing evidence that peripheral inflammatory mediators can cross the blood-brain barrier or activate peripheral-to-central signaling pathways, thereby affecting neuronal health and synaptic plasticity. Elevated Eotaxin and MCP1 may contribute to neurodegeneration or microglial activation in critical brain regions such as the prefrontal cortex and hippocampus, areas heavily implicated in cognitive function.

Furthermore, these insights may pave the way for novel therapeutic strategies aimed at modulating inflammation as a means to alleviate cognitive deficits, which remain largely intractable with current antipsychotic treatments. Targeting chemokine signaling pathways could complement neurotransmitter-based interventions to achieve more comprehensive symptom control.

The study also highlights the utility of multidimensional statistical modeling in psychiatric biomarker discovery, overcoming previous limitations related to single-factor analyses. By integrating immune markers with clinical and cognitive measures, researchers are closer to defining actionable biomarker profiles that can inform personalized medicine approaches.

However, the authors acknowledge the study’s limitations, including its modest sample size and cross-sectional design. Future research should explore longitudinal dynamics of inflammatory markers in relation to illness phases and treatment responses, as well as validating findings in larger, more heterogeneous cohorts to strengthen generalizability.

In sum, the work by Luan and colleagues significantly advances the understanding of schizophrenia’s immune-inflammatory interface, identifying Eotaxin and MCP1 as promising biomarkers linked to cognitive dysfunction. This line of investigation fosters hope for biomarker-driven diagnostic tools and innovative immunomodulatory therapies, ultimately aiming to improve outcomes in this challenging neuropsychiatric disorder.

As the field continues to evolve, integrating immunopsychiatry with cognitive neuroscience holds promise to unravel the complex biological networks underlying schizophrenia and translate these insights into clinical practice. The potential to detect and therapeutically target peripheral inflammatory drivers offers a transformative avenue to mitigate cognitive impairments that profoundly impact patients’ lives.

This study epitomizes the growing interdisciplinary effort bridging immunology, psychiatry, and neurobiology, opening a new frontier in schizophrenia research where blood-based inflammatory signatures serve as accessible windows into brain health and disease mechanisms. Ongoing investigations will determine whether these findings herald a new era of biomarker-guided care and immune-targeted interventions in schizophrenia.

Subject of Research: Cognitive dysfunction in schizophrenia and its association with peripheral blood inflammatory markers

Article Title: Cognitive dysfunction in schizophrenia: association with peripheral blood inflammatory signatures

Article References:
Luan, P., Wang, Q., Sun, Y. et al. Cognitive dysfunction in schizophrenia: association with peripheral blood inflammatory signatures. BMC Psychiatry 25, 1020 (2025). https://doi.org/10.1186/s12888-025-07479-8

Image Credits: AI Generated

DOI: https://doi.org/10.1186/s12888-025-07479-8